Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAspira Pathlab & Diagnostics Ltd 2CINL85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1.25 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Devyangi Patel Designation: Company Secretary EmailId: info@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishna Talawadekar Designation: Chief Financial Officer EmailId: info@aspiradiagnostics.com Date: 26/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholding for the Period Ended March 31, 2021

Aspira Pathlab & Diagnostics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
20-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Certificate Under Regulation 40(10) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2021

Pursuant to Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the certificate for half-year ended March 31, 2021, duly signed by Mr. S.K. Pandey, Practicing Company Secretaries, pursuant to the provisions under Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
13-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliance-Compliance Certificate For Period Ended March 31, 2021

Pursuant to Regulation 7(3) of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby submit the Compliance Certificate for half year ended March 31, 2021.
09-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit a copy of certificate received from Link Intime (India) Private Limited, Registrar and Share Transfer Agent of the Company, certifying that for the quarter ended March 31, 2021.
09-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended March 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dr Pankaj ShahDesignation :- Managing Director / Whole Time Director
09-04-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window

The financial results of the Company for the quarter and year ending March 31, 2021 will be declared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to the above captioned matter, we would like to inform you that pursuant to the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for Prevention of Insider Trading ('Code'), the trading window for dealing in securities of the Company will remain closed from April 1, 2021 till 48 Hours after the said Financial Results are communicated to Stock Exchange.
31-03-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we are enclosing herewith the copy of Newspaper advertisement of the Unaudited Financial Results for the quarter ended 31st December 2020 published in Business Standard and Mumbai Lakshadeep on February 15, 2021 for your reference and record.
17-02-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Appointment of Company Secretary and Compliance Officer

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III of said Regulations, we would like to inform you that based on the recommendation of Nomination & Remuneration Committee, the Board of Directors of the Company at its meeting held on 13th February, 2021, have approved appointment of Ms. Devyangi Patel as Company Secretary and Compliance Officer of the Company, with effect from 17th February, 2021.
13-02-2021
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Appointment Of Chief Financial Officer And Key Managerial Personnel (KMP) Of The Company Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, we would like to inform you that based on the recommendation of Nomination & Remuneration Committee and Audit Committee, the Board of Directors of the Company at its meeting held on 13th February, 2021, have approved appointment of Mr. Balakrishna Talawadekar as Chief Financial Officer and Key Managerial Personnel of the Company with effect from 13th February, 2021.
13-02-2021
Next Page
Close

Let's Open Free Demat Account